Media Contacts

For more information contact our media team:

Stacy Sevcik
+1 314 529 3062
Send Email >

Next Event

  • e-Health Research International Congress 2016

    Paris, France
    Oct11 – 12, 2016

    Learn More

Kantar Health thought leaders are available to comment on a variety of healthcare- and pharma-industry-related topics. In addition, our proprietary data is available for media use, including patient population sizes, treatment rates and patient-reported behaviors and attitudes.

Welcome to the Kantar Health News Room RSS Feed News

Delivering the most current and unique insights on healthcare trends and news about Kantar Health.

Kantar Health Presents Key Highlights from ASCO 2011

Sep 9, 2011

Kantar Health Oncology Experts and Synix Inc. to Host 7th Annual Seminar in Tokyo

NEW YORK, June 21, 2011—Kantar Health, a leading healthcare-focused global consultancy and marketing insights company, today announced that it will host a seminar for pharmaceutical companies highlighting key research from the 2011 American Society of Clinical Oncology (ASCO) annual meeting. The seminar is presented in conjunction with Synix Inc., Kantar Health’s partner in Japan.

The seminar, “Key Highlights from ASCO 2011,” will take place at Conference Square M+ in Tokyo on Thursday, July 14 from 1 to 5 pm and will be led by Kantar Health oncology specialists Gordon Gochenauer, Director, and Neesha Suvarna, Ph.D., Associate Consultant. The presentation will focus on findings involving drugs in development for the major tumor types in Japan, including:

  • Sarcoma: Is Sarcoma the Next Renal Cell Carcinoma? (pazopanib and ridaforolimus)
  • Ovarian: Is Avastin Better Suited in Later Lines? (Avastin plus carboplatin/gemcitabine and olaparib)
  • Melanoma: The Game Has Changed! (Yervoy and vemurafenib)
  • Non-Small Cell Lung Cancer: Advances in Personalized Care (crizotinib, Tarceva and cMET inhibitors)
  • Breast: Is Improving Overall Survival an Insurmountable Barrier for First-Line Trials? (iniparib)
  • Prostate: Sequencing Recent Approvals and the Implication of Circulating Tumor Cells for Future Development (Zytiga, Jevtana and Provenge)
  • Renal Cell Carcinoma: Can the Market Sustain Further Entrants? (Axitinib versus Nexavar, Votrient and tivozanib)
  • Pancreatic: Potential New Options in the Future (TS-1 in combination with gemcitabine)
  • Myeloproliferative Neoplasms: A New Standard in a Previously Recalcitrant Disease (JAK 2 inhibitors)

To register for “Key Highlights from ASCO 2011,” please visit www.synix.co.jp or contact Kousuke Kitamura, Synix Oncology Market Assessment, Synix Inc., at market.assessment@synix.co.jp.

About CancerMPact®

CancerMPact® is an invaluable oncology decision support tool for market analysis, strategic planning, and identification of commercial opportunities in the U.S., Western Europe, Japan and China. This tool is composed of web-based integrated modules: Treatment Practices and Evolution, Patient Metrics, and Monthly Drugs and Regimens. More than 30 tumor types are covered within the modules. Custom studies are available upon request.

Every year since 2005 senior members of the CancerMPact team have traveled to Tokyo to present this seminar on highlights from the ASCO meeting.

Share